BACKGROUND: No consensus exists about which cutoff point should be applied for serum vitamin B-12 (SB-12) concentrations to define vitamin B-12 status in population-based research. OBJECTIVE: The study's aim was to identify whether a change point exists at which the relation between plasma methylmalonic acid (MMA) and SB-12 changes slope to differentiate between inadequate and adequate vitamin B-12 status by using various statistical models. DESIGN: We used data on adults (≥19 y; n = 12,683) from NHANES 1999-2004-a nationally representative, cross-sectional survey. We evaluated 6 piece-wise polynomial and exponential decay models that used different control levels for known covariates. RESULTS: The MMA-defined change point for SB-12 varied depending on the statistical model used. A linear-splines model was determined to best fit the data, as determined by the approximate permutation test; 3 slopes relating SB-12 and MMA and resulting in 2 change points and 3 subgroups were shown. The first group (SB-12 <126 pmol/L) was small and had the highest MMA concentration (median: 281 nmol/L; 95% CI: 245, 366 nmol/L; n = 157, 1.2%); many in this group could be considered at high risk of severe deficiency because combined abnormalities of MMA and homocysteine were very frequent and the concentrations themselves were significantly higher. The highest SB-12 group (SB-12 >287 pmol/L; n = 8569, 67.6%) likely had adequate vitamin B-12 status (median MMA: 120 nmol/L; 95% CI: 119, 125 nmol/L). The vitamin B-12 status of the sizable intermediate group (n = 3957, 33%) was difficult to interpret. CONCLUSIONS: The 3 distinct slopes for the relation between SB-12 and MMA challenges the conventional use of one cutoff point for classifying vitamin B-12 status. In epidemiologic research, the use of one cutoff point would fail to separate the small, severely deficient group from the intermediate group that has neither normal nor clearly deficient vitamin B-12 concentrations (ie, unknown vitamin B-12 status). This intermediate group requires further characterization.
BACKGROUND: No consensus exists about which cutoff point should be applied for serum vitamin B-12 (SB-12) concentrations to define vitamin B-12 status in population-based research. OBJECTIVE: The study's aim was to identify whether a change point exists at which the relation between plasma methylmalonic acid (MMA) and SB-12 changes slope to differentiate between inadequate and adequate vitamin B-12 status by using various statistical models. DESIGN: We used data on adults (≥19 y; n = 12,683) from NHANES 1999-2004-a nationally representative, cross-sectional survey. We evaluated 6 piece-wise polynomial and exponential decay models that used different control levels for known covariates. RESULTS: The MMA-defined change point for SB-12 varied depending on the statistical model used. A linear-splines model was determined to best fit the data, as determined by the approximate permutation test; 3 slopes relating SB-12 and MMA and resulting in 2 change points and 3 subgroups were shown. The first group (SB-12 <126 pmol/L) was small and had the highest MMA concentration (median: 281 nmol/L; 95% CI: 245, 366 nmol/L; n = 157, 1.2%); many in this group could be considered at high risk of severe deficiency because combined abnormalities of MMA and homocysteine were very frequent and the concentrations themselves were significantly higher. The highest SB-12 group (SB-12 >287 pmol/L; n = 8569, 67.6%) likely had adequate vitamin B-12 status (median MMA: 120 nmol/L; 95% CI: 119, 125 nmol/L). The vitamin B-12 status of the sizable intermediate group (n = 3957, 33%) was difficult to interpret. CONCLUSIONS: The 3 distinct slopes for the relation between SB-12 and MMA challenges the conventional use of one cutoff point for classifying vitamin B-12 status. In epidemiologic research, the use of one cutoff point would fail to separate the small, severely deficient group from the intermediate group that has neither normal nor clearly deficient vitamin B-12 concentrations (ie, unknown vitamin B-12 status). This intermediate group requires further characterization.
Authors: Helga Refsum; Eha Nurk; A David Smith; Per M Ueland; Clara G Gjesdal; Ingvar Bjelland; Aage Tverdal; Grethe S Tell; Ottar Nygård; Stein E Vollset Journal: J Nutr Date: 2006-06 Impact factor: 4.798
Authors: Joshua W Miller; Marjorie G Garrod; Alan L Rockwood; Mark M Kushnir; Lindsay H Allen; Mary N Haan; Ralph Green Journal: Clin Chem Date: 2005-12-29 Impact factor: 8.327
Authors: Robert Clarke; Helga Refsum; Jacqueline Birks; John Grimley Evans; Carole Johnston; Paul Sherliker; Per M Ueland; Joern Schneede; Joseph McPartlin; Ebba Nexo; John M Scott Journal: Am J Clin Nutr Date: 2003-05 Impact factor: 7.045
Authors: Elizabeth Selvin; Jane Manzi; Lesley A Stevens; Frederick Van Lente; David A Lacher; Andrew S Levey; Josef Coresh Journal: Am J Kidney Dis Date: 2007-12 Impact factor: 8.860
Authors: Christine M Pfeiffer; John D Osterloh; Jocelyn Kennedy-Stephenson; Mary Frances Picciano; Elizabeth A Yetley; Jeanne I Rader; Clifford L Johnson Journal: Clin Chem Date: 2008-03-28 Impact factor: 8.327
Authors: L C Pennypacker; R H Allen; J P Kelly; L M Matthews; J Grigsby; K Kaye; J Lindenbaum; S P Stabler Journal: J Am Geriatr Soc Date: 1992-12 Impact factor: 5.562
Authors: Lindsay H Allen; Joshua W Miller; Lisette de Groot; Irwin H Rosenberg; A David Smith; Helga Refsum; Daniel J Raiten Journal: J Nutr Date: 2018-12-01 Impact factor: 4.798
Authors: J P van Wijngaarden; R A M Dhonukshe-Rutten; E M Brouwer-Brolsma; A W Enneman; K M A Swart; S C van Dijk; P H In 't Veld; N M van Schoor; N van der Velde; R de Jonge; P Lips; A G Uitterlinden; L C P G M de Groot Journal: J Nutr Health Aging Date: 2017 Impact factor: 4.075
Authors: Christine M Pfeiffer; David A Lacher; Rosemary L Schleicher; Clifford L Johnson; Elizabeth A Yetley Journal: Adv Nutr Date: 2017-03-15 Impact factor: 8.701
Authors: Rima Obeid; Susanne H Kirsch; Sarah Dilmann; Cosima Klein; Rudolf Eckert; Jürgen Geisel; Wolfgang Herrmann Journal: Eur J Nutr Date: 2015-05-06 Impact factor: 5.614
Authors: Anne M Molloy; Faith Pangilinan; James L Mills; Barry Shane; Mary B O'Neill; David M McGaughey; Aneliya Velkova; Hatice Ozel Abaan; Per M Ueland; Helene McNulty; Mary Ward; J J Strain; Conal Cunningham; Miriam Casey; Cheryl D Cropp; Yoonhee Kim; Joan E Bailey-Wilson; Alexander F Wilson; Lawrence C Brody Journal: Am J Hum Genet Date: 2016-04-28 Impact factor: 11.025
Authors: Regan L Bailey; Anne C Looker; Zhaohui Lu; Ruzong Fan; Heather A Eicher-Miller; Tala H Fakhouri; Jaime J Gahche; Connie M Weaver; James L Mills Journal: Am J Clin Nutr Date: 2015-07-29 Impact factor: 7.045
Authors: Bruce H R Wolffenbuttel; Hanneke J C M Wouters; M Rebecca Heiner-Fokkema; Melanie M van der Klauw Journal: Mayo Clin Proc Innov Qual Outcomes Date: 2019-05-27